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124 Poster Session-IIMethods: 24 clinicians, (‘‘non-expert MD’’, n 5 16; ‘‘non-expert
non-MD’’; n5 4; and oral ‘‘expert’’, n5 4), from six major transplant
centers scored high-quality intraoral photographs of 12 patients.
The same photographs were evaluated 1 week later by the same eval-
uators. An intra-class correlation coefficient (ICC) was used to calcu-
late intra-rater reliability and inter-rater agreement was analyzed
using a weighted k statistic: 0 # k # 0.20 5 poor, 0.21 # k # 0.40
5 fair, 0.41 # k # 0.60 5 moderate, 0.61 # k # 0.80 5 good,
0.81 # k # 1.00 5 very good. Data on participant experiences and
demographics were also collected.
Results: Mean inter-rater reliability for each element was poor to
moderate (range 0.15 – 0.46). Overall mean kappa scores were high-
est for ULCERS (0.46), followed by ERYTHEMA (0.23) and lowest
for LICHENOID (0.15) and MUCOCELES (0.14). Kappa scores
were higher in ‘‘expert’’ compared with ‘‘non-expert MD’’ and
‘‘non-expert non-MD’’ in ULCERS and ERYTHEMA (e.g. 0.85,
0.44, 0.33 for ULCERS, respectively), but similar in LICHENOID
and MUCOCELES. Overall intra-rater reliability in all groups was
very good ($0.90) and highest for ULCERS (0.97, 0.85, 0.94).
While 75% of ‘‘experts’’ were comfortable with their abilities to score
the cases, approximately 50% of ‘‘non-experts’’ were uncomfortable.
The majority felt that their evaluations were accurate, however
84% agreed that formal training is required.
Conclusions: Inter-rater variability of the oral cGVHD instru-
ment is unacceptable for the purposes of clinical trials. Greater con-
cordance among ‘‘experts’’, high intra-rater reliability, and
participant feedback suggests that formal training may significantly
decrease variability. Parallel investigations must be completed using
the other organ specific instruments prior to any revision and wide-
spread prospective utilization of these tools as research endpoints.346
INTERACTIONS BETWEEN DC AND T-CELLS INITIATE COUNTER-REGU-
LATORY IMMUNE ACTIVITIES THAT LIMITS AMPLIFICATION OF ALLO-IM-
MUNE RESPONSES AND GvHD
Lu, Y., Li, J.-M., Harris, W., Waller, E. Winship Cancer Institute,
Emory University, Atlanta, GA
Acute graft-versus-host disease (GvHD) remains a major compli-
cation following allogenic hematopoietic stem cell transplant
(HSCT). Our reports and several publications have suggested a po-
tential beneficial effect of donor DC during HSCT. Using allogeneic
MHC-mismatched HSCT mice model, we previously demonstrated
that recipients transplanted with FACS-purified CD11b- DC with
HSC and T-cells had increased GvL and limited GvHD. In the cur-
rent study, we found that transplantation of T-cells from IFN-g
knock-out mice resulted in severe GvHD and higher levels of Th17
cells compared with recipients of T-cells from wide-type (WT)
mice, suggesting that donor T-cell synthesis of IFN-g induced by
donor DC is necessary to augment expansion of allo-reactive T-cells
that mediate GvL while subsequently limiting generalized activation
of donor T-cells that lead to off-target effects and GvHD. In order to
further clarify the mechanisms involved in the action of donor DC on
the limitation of GvHD, we detected the level of the IFN-g-induc-
ible indoleamine-2,3-dioxygenase(IDO) protein, which has been re-
ported to exert inhibitory effects on T cells activity, on donor DCs
and its potential roles in regulating donor T cell allo-immune activ-
ity. We set up an in vitro co-culture system including purified
CD11b- DC from WT or IDO knock-out mice and CFSE-labeled
syngeneic T cells in the presence of allogeneic antigen. T-cells co-
cultured with CD11b- DC had higher proliferation rates compared
with T-cells cultured with allo-antigen in the absence of DCs. Fur-
thermore, CD8 T-cells proliferated earlier and more than CD4
T-cells in response to alloantigen in the presence of CD11b- DC,
suggesting CD8 T-cells be mainly responsible for the observed
GvL activity in murine model systems. IDO expression on WT
CD11b- DC was increased in 3–7 day cultures containing syngeneic
T cells and allo-antigen but not on DC cultured with allo-antigen
alone. Thus, IFN-g-induced IDO expression on CD11b- donor
DCs might be a critical downstream event that inhibits continued
T-cell activation by initiating counter-regulatory immune activities
that limit allo-immune responses. Interestingly, T cells co-cultured
with CD11b1 DC from IDO knock-out donors had higher prolifera-tion rate than T cells co-cultured with CD11b- DC on day-7. Fur-
ther studies using IDO knock-out mice as DC donors in our
C57BL/6/B10.BR transplant model are essential to understand
the role of IDO expression of DC in allogeneic HSCT.347
INHIBITION OF GSK3 AND mTOR ENHANCES THE STEMNESS OF ACTI-
VATED CD81 T CELLS
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Memory T cells have the ability to vigorously proliferate and to
generate differentiated effector cells upon reencounter of the cog-
nate antigen, while self-renewing. This stemness property of mem-
ory T cells has been explored for adoptive T cell immunotherapy.
On the other hand, it may be particularly difficult to treat memory
T cell-mediated inflammatory disorders, such as graft-versus-host
disease (GVHD) among others, unless long-lived memory T cells
are effectively targeted. However, the molecular mechanisms that
regulate the stemness of memory T cells remain unknown. Using
mouse GVHD models, we have previously identified a population
of alloreactive postmitotic CD44loCD62LhiCD81 memory T cells
(TPM) that induce GVHD. These TPM cells are able to generate
all subsets of effector and memory T cells and have greater ability
than both effector memory T cells (TEM) and central memory T cells
(TCM) to proliferate, while self-renewing. These data suggest that
TPM cells contain higher frequency of T memory stem cells than
other memory T cell subsets. In the present study, we found that
these TPM cells were initially generated during host antigen-priming
of donor T cells and persisted throughout the disease course. Gene
microarray analysis revealed that TPM cells represented the earliest
antigen-experienced CD81 T cells to become effector and memory
T cells, whereas TEM cells were terminally differentiated cells. As
comparison, TCM cells were the intermediates between TPM cells
and TEM cells. Interestingly, during differentiation of TPM cells to
TEM cells, Wnt-signaling activity was dramatically decreased,
whereas mTOR activity was augmented. A similar molecular profil-
ing of alloreactive T cells was also found in activated TCR-trans-
genic CD81 T cells specific to LCMV gp33 peptide. Inhibition of
either GSK3 or mTOR during antigenic-priming of CD81 T cells
significantly enhanced the generation of memory T cells specific to
gp33 peptide. Thus, both GSK3- and mTOR-mediated signals
play important roles in regulating the stemness of activated CD81
T cells. These findings have significant implications in the develop-
ment of new methods to treat ongoing GVHD and to augment adop-
tive T cell cancer therapy.348
OPTIMIZATION OF ALEMTUZUMAB DOSE FOR GRAFT-VERSUS-HOST DIS-
EASE PROPHYLAXIS FOR REDUCED INTENSITY TRANSPLANTATION
FROM UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC
MALIGNANCIES
Gupta, V.1, Xu, W.2, Sutherland, R.3, Kamel-Reid, S.3, Kuruvilla, J.1,
Loach, D.1, Lipton, J.H.1, Messner, H.A.1 1Princess Margaret Hospital,
Toronto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Can-
ada; 3University Health Network, Toronto, ON, Canada
It has been shown that a high dose of alemtuzumab (100mg) in
combination with cyclosporine (CsA) significantly reduces the risk
of acute and chronic GVHD, however a high risk of relapse compro-
mises the transplant outcomes. We hypothesized that a lower dose of
alemtuzumab for GVHD prophylaxis may help in achieving a bal-
ance between prevention of severe GVHD while preserving
a Graft-versus-leukemia (GVL) effect. We studied the use of a lower
dose of alemtuzumab with CsA as GVHD prophylaxis in 36 patients
undergoing reduced intensity conditioning (RIC) using matched un-
related donors. The study includes two sequential cohorts treated at
Princess Margaret Hospital between September 2004 and July 2007:
cohort 1 (n 5 17) received 60 mg of IV alemtuzumab (10mg, 20mg
and 30 mg on days –8,27 and –6); cohort 2 (n5 19) received 30 mg
